13-4　ⓔ文献

  1. Kuo CF, Grainge MJ, et al: Familial Aggregation of systemic lupus erythematosus and coaggregation of autoimmune diseases in affected families. JAMA Intern Med, 2015; 175: 1518–1526.

  2. Alarcón–Segovia D, Alarcón–Riquelme ME, et al: Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohort. Arthritis Rheum, 2005; 52: 1138–1147.

  3. Block SR, Winfield JB, et al: Studies of twins with systemic lupus erythematosus. A review of the literature and presentation of 12 additional sets. Am J Med, 1975; 59: 533–552.

  4. Pons–Estel GJ, Alarcón GS, et al: Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum, 2010; 39: 257–268.

  5. Bentham J, Morris DL, et al: Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus. Nat Genet, 2015; 47: 1457–1464.

  6. Morris DL, Sheng Y, et al: Genome–wide association meta–analysis in Chinese and European individuals identifies ten new loci associated with systemic lupus erythematosus. Nat Genet, 2016; 48: 940–946.

  7. Yeung KS, Chung BH, et al: Genome–wide DNA methylation analysis of Chinese patients with systemic lupus erythematosus identified hypomethylation in genes related to the type I interferon pathway. PLoS One, 2017; 12: e0169553.

  8. Arbuckle MR, McClain MT, et al: Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med, 2003; 349: 1526–1533.

  9. Lawrence RC, Helmick CG, et al: Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum, 1998; 41: 778–799.

  10. Chakravarty EF, Bush TM, et al: Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained using hospitalization data. Arthritis Rheum, 2007; 56: 2092–2094.

  11. Danchenko N, Satia JA, et al: Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus, 2006; 15: 308–318.

  12. Peschken CA, Esdaile JM: Rheumatic diseases in North America’s indigenous peoples. Semin Arthritis Rheum, 1999; 28: 368–391.

  13. Cervera R, Khamashta MA, et al: Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore), 1993; 72: 113–124.

  14. Mina R, Brunner HI: Update on differences between childhood–onset and adult–onset systemic lupus erythematosus. Arthritis Res Ther, 2013; 15: 218.

  15. Tsokos GC, Lo MS, et al: New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol, 2016; 12: 716–730.

  16. Dieker J, Tel J, et al: Circulating apoptotic microparticles in systemic lupus erythematosus patients drive the activation of dendritic cell subsets and prime neutrophils for NETosis. Arthritis Rheumatol, 2016; 68: 462–472.

  17. Herrmann M, Voll RE, et al: Mpaired phagocytosis of apoptotic cell material by monocyte–derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum, 1998; 41: 1241–1250.

  18. Savarese E, Steinberg C, et al: Requirement of Toll–like receptor 7 for pristane–induced production of autoantibodies and development of murine lupus nephritis. Arthritis Rheum, 2008; 58: 1107–1115.

  19. Pawar RD, Ramanjaneyulu A, et al: Inhibition of Toll–like receptor–7 (TLR–7) or TLR–7 plus TLR–9 attenuates glomerulonephritis and lung injury in experimental lupus. J Am Soc Nephrol, 2007; 18: 1721–1731.

  20. Papadimitraki ED, Choulaki C, et al: Expansion of toll–like receptor 9–expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process. Arthritis Rheum, 2006; 54: 3601–3611.

  21. Baechler EC, Batliwalla FM, et al: Interferon–inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA, 2003; 100: 2610–2615.

  22. Kirou KA, Lee C, et al: Coordinate overexpression of interferon–alpha–induced genes in systemic lupus erythematosus. Arthritis Rheum, 2004; 50: 3958–3967.

  23. Gaitonde S, Samols D, et al: C–reactive protein and systemic lupus erythematosus. Arthritis Rheum, 2008; 59: 1814–1820.

  24. Crispín JC, Oukka M, et al: Expanded double negative T cells in patients with systemic lupus erythematosus produce IL–17 and infiltrate the kidneys. J Immunol, 2008; 181: 8761–8766.

  25. Minowa K, Amano H, et al: Disease flare patterns and predictors of systemic lupus erythematosus in a monocentric cohort of 423 Japanese patients during a long–term follow–up: The JUDE study. Mod Rheumatol, 2017; 27: 72–76.

  26. 橋本博史：SLEの疫学．全身性エリテマトーデス臨床マニュアル 第3版，日本医事新報社，2017; 9–21.

  27. Weening JJ, D’Agati VD, et al: The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol, 2004; 15: 241–250.

  28. Bajema IM, Wilhelmus S, et al: Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int, 2018; 93: 789–796.

  29. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum, 1999; 42: 599–608.

  30. Tan EM, Cohen AS, et al: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum, 1982; 25: 1271–1277.

  31. Hochberg MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum, 1997; 40: 1725.

  32. Petri M, Orbai AM, et al: Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum, 2012; 64: 2677–2686.

  33. Aringer M, Costenbader K, et al: 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis, 2019; 78: 1151–1159.

  34. Doria A, Iaccarino L, et al: Long–term prognosis and causes of death in systemic lupus erythematosus. Am J Med, 2006; 119: 700–706.

  35. 市川陽一，吉田　正，他：SLEの臓器病変と予後判定．臨床免疫．1987; 19: 582–590.

  36. 厚生労働科学研究費補助金難治性疾患等政策研究事業 自己免疫疾患に関する調査研究 (自己免疫班)，日本リウマチ学会編：全身性エリテマトーデス診療ガイドライン2019，南山堂，2019; xvii.

  37. Fanouriakis A, Kostopoulou M, et al: 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis, 2019; 78: 736–745.

  38. Hahn BH, McMahon MA, et al: American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken), 2012; 64: 797–808.

  39. Morand EF, Furie R, et al: Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med, 2020; 382: 211–221.

  40. Shinjo SK, Bonfá E, et al: Antimalarial treatment may have a time–dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum, 2010; 62: 855–862.

  41. Jung H, Bobba R, et al: The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum, 2010; 62: 863–868.

  42. Marmor MF, Kellner U, et al: Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology, 2016; 123: 1386–1394.